Last Thursday, the New England Journal of Medicine published the results of Impact, the pivotal clinical trial that persuaded the FDA to approve Dendreon (DNDN) Provenge in late April.
Showing posts with label Dendreon. Show all posts
Showing posts with label Dendreon. Show all posts
Wednesday, August 04, 2010
Saturday, May 02, 2009
Dendreon (DNDN) Lightening Strikes Twice (Chart)
Dendreon (DNDN) Lightening Strikes Twice
Weekly Chart.
If you owned it, you had a shot to make 10 times your dojo.
65 day high 27.40. 65 day low 2.55.
Amazing. Dendreon (DNDN) traded up like an oil gusher in 2007, high 25.25, and back down to 2.55 in March, 2009. It did it again this year, high 27.40.
What is next for Dendreon. Beats me, mighty risky for sure. Fundamental story is interesting. Feel free to add your two cents in the comments box.
Follow All American Investor on Twitter
Weekly Chart.
If you owned it, you had a shot to make 10 times your dojo.
65 day high 27.40. 65 day low 2.55.
Amazing. Dendreon (DNDN) traded up like an oil gusher in 2007, high 25.25, and back down to 2.55 in March, 2009. It did it again this year, high 27.40.
What is next for Dendreon. Beats me, mighty risky for sure. Fundamental story is interesting. Feel free to add your two cents in the comments box.
Subscribe to All American Investor via Email
Follow All American Investor on Twitter
Tuesday, April 28, 2009
Dendreon (DNDN) Hot Chart
Dendreon Corporation (DNDN). Did you own this stock? Well somebody did and it wasn't me. The stock has risen from the 4.25 area to the 22.50 area in the last 20 days.
Note: news due today at 2 PM eastern.
Dendreon Corporation (DNDN), a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients.
Dendreon applies its expertise in antigen identification, engineering and cell processing to produce Active Cellular Immunotherapy (ACI) product candidates designed to stimulate an immune response. ACI holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. In addition to ACI product candidates, the company is researching small molecule product candidates.
Dendreon Newsroom
Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 agonist, D-3263, in Benign Prostatic Hyperplasia
More from All American Investor
Follow All American Investor on Twitter
Note: news due today at 2 PM eastern.
Dendreon Corporation (DNDN), a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients.
Dendreon applies its expertise in antigen identification, engineering and cell processing to produce Active Cellular Immunotherapy (ACI) product candidates designed to stimulate an immune response. ACI holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. In addition to ACI product candidates, the company is researching small molecule product candidates.
Dendreon Newsroom
Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 agonist, D-3263, in Benign Prostatic Hyperplasia
Subscribe to All American Investor via Email
 Bob DeMarco is a citizen journalist and twenty year Wall Street veteran. Bob has written more than 500 articles with more than 11,000 links to his work on the Internet. Content from All American Investor has been syndicated on Reuters, the Wall Street Journal, Fox News, Pluck, Blog Critics, and a growing list of newspaper websites. Bob is actively seeking syndication and writing assignments. |
More from All American Investor
- 30 Year Conventional Mortgage Rate (Chart)
- Top Hedge Fund Managers Make Billions in 2008
- Systemic Risk Defined--Too Big to Fail
- Ray Dalio on the current state of affairs in the market
- Roubini Predicts U.S. Losses May Reach $3.6 Trillion
- Option ARM--The Toxic Mortgage
- Warren Buffett's Annual Letter to Investors (Cliff Notes Version)
Follow All American Investor on Twitter
Subscribe to:
Posts (Atom)